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ABSTRACT 
 
Background: To date, potential coeliac disease (PCD) occurring in adults remains an almost 
unexplored condition. Aims: to explore the prognostic role of Marsh grade in adult PCD patients, 
and to evaluate the effects of gluten-containing diet (GCD) in asymptomatic PCD patients. 
Methods: We retrospectively evaluated all consecutive adult PCD patients followed-up for at least 
6 years. Patients were divided into: Group A (patients with Marsh 0 histology) and Group B (Marsh 
1 patients). Symptomatic patients were started gluten-free diet (GFD), while asymptomatic subjects 
were kept on GCD and were followed-up. Results: 56 PCD patients were enrolled (21 in Group A 
and 35 in Group B). Forty-three patients were symptomatic and started GFD. Of these, none of 15 
patients in Group A and 8 of 28 patients in Group B developed immune-mediated disorders (IMD) 
during follow-up (P=0.03; OR=4.2). The 13 asymptomatic PCD patients were kept on GCD. 
During the follow-up, 9 patients developed CD-related symptoms, 6 villous atrophy and 8 IMD. At 
the end, patients kept on GCD were at higher risk of developing IMD than those following a GFD 
(61% vs 18%, P=0.03, OR=3.3). Conclusions: Although PCD with normal mucosa seems to be a 
milder disease, the continuation of GCD places patients at a high risk of developing villous atrophy 
and IMD compared to commencement of GFD. Adult PCD patients should start GFD even if not 
symptomatic. 
 
KEYWORDS: Potential coeliac disease, Marsh, villous atrophy, immuno-mediated disorders 
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INTRODUCTION 
 
Coeliac disease (CD) is the most common immuno-mediated enteropathy in Western countries, 
triggered by exposure to gluten in genetically predisposed individuals (HLA DQ2/DQ8) [1,2]. 
At present, CD diagnosis in adults requires the serological assessment (anti-tissue transglutaminase 
[a-tTG] and anti-endomysial [EMA] antibodies [3]) of patients with suspected CD, and duodenal 
biopsy to evaluate the intestinal damage in patients with positive CD serology, although some 
patients are found and diagnosed based on histology only (only the minority of cases) [4].  
In the majority of CD patients, small bowel damage consists of villous atrophy, intraepithelial 
lymphocytosis (IEL) and crypt hyperplasia [5]. These histological changes were classified by 
Marsh [6] into three different histological patterns: Marsh 1 (IEL>25/100 enterocytes), Marsh 2 
(IEL>25/100 enterocytes and crypt hyperplasia), Marsh 3 (IEL>25/100 enterocytes, crypt 
hyperplasia and villous atrophy). 
Although current CD diagnostic criteria require the presence of villous atrophy, this microscopic 
damage characterizes only the end stage of the disease; indeed many authors suggest that CD 
pathogenesis gradually leads from inflammatory damage to crypt hyperplasia and, ultimately, to 
villous atrophy [7]. 
Furthermore, a growing number of CD patients shows the absence of bowel damage or the sole 
increase of IELs at duodenal biopsy, findings which define the Marsh 0 and 1 types, respectively. 
At present, the term “potential CD” (PCD) is used to refer to those patients who have HLA-DQ2 
and/or DQ8, a-tTG positivity but normal histology (Marsh 0) or low-grade enteropathy (Marsh 1) 
[8,9]. Moreover, since a-tTG antibodies display about 10% of false positive results, particularly 
when being positive at a very low titer, EMA positivity is also recommended before classifying a 
patient as affected by PCD. 
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Although several pediatric studies have been published on PCD [10, 11], adult PCD remains an 
almost unexplored condition [12–15].  
One of the most interesting (but unresolved) issues in the context of PCD regards the extent to 
which patients actually need to start a gluten-free-diet (GFD) and the long-term risk for those 
remaining on a gluten-containing diet (GCD) [11–15].  
The aim of the present study was to explore the long-term prognostic role of Marsh grade in adult 
PCD patients, comparing clinical and serologic features at the time of diagnosis in subjects with 
Marsh 0 and 1 histology and monitoring the development of autoimmune disorders and neoplastic 
complications in the same subjects after PCD diagnosis. In addition, our study also examined the 
effects of a GCD in asymptomatic PCD patients to determine how many would develop gluten-
related symptoms, villous atrophy, and/or autoimmune diseases, and whether the initial Marsh 
grade may be contributing to the outcome.  
 
MATERIALS AND METHODS 
 
Study population and study design 
We carried out a retrospective study in adult PCD patients referred to our Gastrointestinal Unit 
(Tertiary Centre for Food Intolerance and CD) at the “Federico II” School of Medicine, Naples, 
Italy, during the years 2008 – 2010, for clinical suspicion of CD (diarrhea, steatorrhea, weight loss, 
growth failure, abdominal pain, bloating, anemia, osteopenia/osteoporosis, recurrent miscarriages, 
hepatic steatosis, dental enamel hypoplasia, alopecia, hypertransaminasemia, recurrent aphthous 
stomatitis) or risk of CD (Hashimoto’s thyroiditis, Down Syndrome, type-1 Diabetes Mellitus, 
positive family history of CD), and who completed a follow-up period of at least 6 years. All study 
participants were tested for EMA (absent/present) and anti-tTG levels (U/ml) at our laboratory. 
Patients with positive serology underwent upper endoscopy with duodenal biopsies/histology. 
Diagnosis of potential CD was made in accordance with current Guidelines [8, 9], that is in the 
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presence of positive serology (for both a-tTG and EMA), normal histology (Marsh 0) or low-grade 
enteropathy (Marsh 1), and genetic susceptibility (HLA DQ2/DQ8).  
On the basis of the Marsh grade at the time of PCD diagnosis, participating patients were divided 
into two groups: Group A comprised individuals with normal histology (Marsh 0) and Group B 
those with Marsh 1 type histology. All patients with symptoms of CD or with other conditions 
related to CD started GFD, in accordance with suggestions of current literature [12], while 
asymptomatic PCD individuals were left on GCD. We compared the two groups in terms of 
anthropometric and serological variables (body weight, haemoglobin, ferritin, blood glucose, 
albumin, cholesterol, triglycerides, anti-tTG IgA) and clinical features (gastrointestinal or extra-
intestinal symptoms) at the time of diagnosis. We then periodically followed up patients on GFD to 
assess their clinical and serological response to the diet, and compared the development of 
autoimmune disorders and neoplastic complications despite GFD in the Marsh 0 and Marsh 1 sub-
groups. 
Asymptomatic PCD patients on GCD underwent clinical and serological follow-up every six 
months, and upper endoscopy with duodenal biopsies/histology every two years. In this group too 
we compared Marsh 0 and 1 patients with regard to the development of gluten-related symptoms, 
villous atrophy, immuno-mediated disorders (IMD) and neoplastic complications. 
Patients who were diagnosed with PCD before the age of 18 were excluded from the study, as were 
patients who received the diagnosis of PCD at other institutes. Also, we excluded from the study all 
patients with discordant or negative antibodies, unclear histology or already on gluten-free diet 
(GFD). 
 
Serology and HLA Typing 
Anti-tissue transglutaminase (anti-tTG) IgA antibodies were measured by ELISA (Enzyme-Linked 
Immunosorbent Assay, automated system; Delta Biologicals SRL) using human recombinant tTG 
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as antigen: serum samples with antibody titer greater than 7 U/mL were considered positive. Tests 
for anti-endomysial (EMA) IgA antibodies were carried out by expert operators; the antibodies 
were identified using immunofluorescence on a section of monkey esophagus (Delta Biologicals 
SRL). Results were expressed qualitatively as either a positive or negative finding (sometimes mild 
positivity). All serological investigations were performed at our Centre’s laboratory at the time of 
CD diagnosis and during the follow-up.  
All patients on GFD were tested for EMA and anti-tTG every 12 months from the time of PCD 
diagnosis; all patients left on GCD were tested for EMA and anti-tTG every six months. 
Furthermore, patients were genotyped for human leukocyte antigen (HLA) class II DRB1 and 
DQB1 molecules (Euroimmun SRL).  
 
Endoscopy and Histology 
Multiple endoscopic duodenal biopsies were obtained by esophagogastroduodenoscopy (EGDS). In 
particular, 4 well-oriented biopsies were obtained in the distal duodenum, while 2 biopsies were 
taken in the duodenal bulb. All patients confirmed to be consuming an unrestricted diet at the time 
of histological evaluation. Histological evaluation was carried out by a pathologist blinded to the 
clinical history. Histological findings were classified according to Marsh classification [6]. More 
specifically, in case of complete absence of intestinal lesions, both on hematoxylin-eosin stained 
sections and at immunohistochemistry for CD3, the patient was classified as Marsh 0, while the 
microscopic damage was estimated as Marsh 1 in the presence of IEL > 25/100 enterocytes and 
positive CD3 immunostaining. The presence of any disease other than CD detected on the basis of 
the results of the upper endoscopy or histology was also recorded. Endoscopic and histological 
evaluation was repeated every two years in PCD patients kept on GCD. 
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Statistical analysis 
Data were analyzed using the Statistical Package for Social Sciences (SPSS software v.15.0) for 
Windows. The descriptive statistics used included calculation of mean values and standard 
deviation (SD) of the continuous variables, and the percentages and proportions of the categorical 
variables. Age at diagnosis, prevalence of symptoms (gastrointestinal or extra-intestinal), immuno-
mediated disorders (IMD), family history and laboratory data were compared by using Student’s t-
test, chi-square test, Fisher’s exact test and ANOVA, as appropriate. The odd ratio (OR) for 
quantifying the statistical difference between the dichotomous variables was also calculated. A p 
value of less than 0.05 was considered statistically significant. 
 
RESULTS 
 
Clinical features of the study population 
During the study period, a total of 56 adult PCD patients, out of the 452 adult patients diagnosed 
with CD at our tertiary centre (12.4%), completed a follow-up period of at least 6 years and met 
diagnostic criteria for inclusion in the study. 
Of these 56 PCD patients (females 73%, mean age 31.4 years), 28 (50%) had at least a first-degree 
relative suffering from CD, and 6 (10.7%) had a previous diagnosis of immuno-mediated disorder 
(IMD). HLA DQ2 alleles were present in 95% of the patients, while 5% expressed HLA DQ8 
haplotype; in particular, 19% of subjects with PCD were found to have DQB1*02 homozygosity, 
while the remaining displayed heterozygosity. With regard to signs and symptoms, 43 (76.7%) 
patients were symptomatic; of these 18 (41.8%) referred to our ambulatory for diarrhoea, abdominal 
pain and weight loss and 25 (58.2%) presented anemia, recurrent miscarriages, hepatic steatosis, 
and hypertransaminasemia. Thirteen patients (23.3%) were asymptomatic. 
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Duodenal biopsies showed Marsh 0 histology in 21 (37.5%) and Marsh 1 in 35 (62.5%) 
participants. In line with these microscopic findings, we divided our study population into two 
groups: Group A, comprised the 21 patients with complete absence of intestinal damage (Marsh 0), 
and Group B the 35 patients with isolated intraepithelial lymphocytosis (Marsh 1). 
No significant differences were found between Group A and B in terms of gender, age at the time of 
PCD diagnosis, HLA haplotype, CD family history, pre-existent immuno-mediated disorders, 
symptoms, and anthropometric and serological variables (Table 1). In particular, mean a-tTG levels 
were 18.9 + 9.3 in Group A and 19.7 + 13.4 in Group B (p=0.8), while all patients displayed EMA 
positivity (titers varying from 1:80 to 1:160). 
In addition, when confronting all PCD patients with those with villous atrophy, we found no 
statistically significant differences in term of age at diagnosis (31.4 vs 31.8, p=NS), gender (females 
73% vs 71%, p=NS), prevalence of symptoms (77% vs 79%, p=NS), associated diseases at CD 
diagnosis (11% vs 16%, p=NS), and family history for CD (50% vs 48%). Moreover, no differences 
were seen in terms of serological variables (haemoglobin, ferritin, cholesterol, triglycerides, serum 
albumin) between PCD and atrophic CD patients (p=NS). On the other hand, patients with PCD 
displayed lower a-tTG titer at diagnosis than atrophic CD patients (19.4 vs 78.2, p<0.001). 
The 43 (76.7%) patients who were symptomatic at the time of diagnosis (15 in Group A and 28 in 
Group B) were placed on GFD followed-up once a year for at least 6 years. After gluten withdrawal 
all these patients became negative for both anti-tTG and EMA antibodies and showed significant 
clinical improvement within 2 years. No specific difference was seen between the two groups in 
terms of response to GFD.  
Despite these good responses and strict adherence to GFD, 8 patients in Group B (28.5%) – but 
none in Group A (P=0.03; OR=4.2 [95% IC 0.5-37.5]) - developed an immuno-mediated disorder 
during follow-up. No neoplastic complications were observed. Table 2 summarizes these results. 
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Clinical features of PCD patients kept on gluten-containing diet 
Thirteen asymptomatic adult PCD patients were kept on a gluten-containing diet (GCD) and 
clinically monitored every six months; endoscopic evaluation was offered every 2 years. Of these, 9 
were women and 38.5% had a first-degree relative suffering from CD. Nobody had a pre-existent 
CD-related IMD. Six patients were in Group A (Marsh 0) and 7 in Group B (Marsh 1).  
During the first two years since PCD diagnosis, all subjects remained asymptomatic and showed no 
changes in Marsh grade at biopsy. However, 4 years after diagnosis 6 patients had developed CD-
related symptoms; 5 patients developed IMD and 3 of them developed villous atrophy. Patients with 
villous atrophy showed higher anti-tTG value compared to non-atrophic patients (mean 54.3 U/mL 
vs 11.4 U/mL, respectively, p<0.01). The 6 patients developing CD-related conditions were placed 
on GFD, with substantial improvement of clinical symptoms and normalization of serum antibodies 
within 12 months.  
The remaining 7 asymptomatic patients without villous atrophy were followed up every six months. 
Six years after PCD diagnosis, 3 of these 7 patients – 1 from Group A and 2 from Group B - had 
developed CD-related symptoms. All 3 patients were found to have atrophic changes on duodenal 
histology and were started on GFD. The two patients from Group B developed an IMD. Only 3 
participants remained asymptomatic and showed persistent Marsh 0 histological features on GCD, 
without developing villous atrophy and/or IMD. In summary, over a 6-year follow-up period, 9 out 
of 13 patients (69%) developed CD-related symptoms, 6 (46%) developed villous atrophy and 8 
(61%) an IMD, without statistically significant differences between groups A and B (Figure 1). 
When we compared patients kept on GCD with those following a GFD, we found that the former 
had a statistically significant higher risk of developing CD-related IMD than the latter (61% vs 
18%, p=0.03, OR=3.3 [95% IC 1.04-10.5]). 
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DISCUSSION 
 
Potential coeliac disease of the adult is an almost unexplored condition [12–14]. Whilst numerous 
pediatric studies have been published [10,11], data on the condition in the adult population are still 
scarce. In view of this, more research is needed to understand the characteristics of this CD 
population and to establish the need for GFD and assess the long-term risk for patients remaining on 
gluten-containing diet (GCD) [11–15]. 
In this paper, we aimed to explore the long-term prognostic role of Marsh grade in adult PCD 
patients on GFD by comparing patients with Marsh 0 and Marsh 1, and the occurrence of 
autoimmune disorders and neoplastic complications after PCD diagnosis. 
Within a study population of 56 adult PCD patients, we found a high rate (50%) of CD family 
history, and a large majority (76.7%) of symptomatic patients. Microscopic evaluation showed 
Marsh 0 histology in 37.5% of patients and Marsh 1 histology in 62.5%. These findings were in line 
with previous studies [12, 14-17]: the high rate of first-degree relatives with CD and the high 
predominance of symptomatic patients could actually explain an increase in serological 
investigations for CD suspicion and, as consequence, an increase in the prevalence of PCD over 
time. More specifically, Volta et al [17], Biagi et al [14] and Zanini et al [13] have reported a PCD 
prevalence of 10.5%, 18.3% and 11%, respectively. In line with these authors’ results, the 
prevalence of adult PCD in our study was 12.4%. Moreover, only 19% of subjects with PCD were 
found to have DQB1*02 homozygosity, in accordance with Biagi et al [18]. Furthermore, we found 
no differences in terms of clinical presentation between PCD patients and age- and sex-matched 
atrophic CD subjects, except in lower a-tTG titer in PCD, as suggested by previous studies [14]. 
When comparing our two groups (Marsh 0 and Marsh 1) at the time of PCD diagnosis, we found no 
significant differences in terms of gender, age at diagnosis, HLA haplotype, CD family history, pre-
existent immuno-mediated disorders, symptoms and anthropometric and serological variables. 
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Recently, Volta and colleagues [17] reported in their series of CD patients a population of adults 
with normal mucosa, finding no significant difference between this population and that with Marsh 
1 in terms of clinical features. In line with these Authors’ findings, we did not detect any 
differences between the two groups at the time of PCD diagnosis. However, during a 6-year follow-
up period and despite participants’ adherence to a strict GFD, we found that 28.5% of Marsh 1 
patients– but none in Marsh 0 Group - developed an immuno-mediated disorder (p=0.03; OR=4.2). 
In our interpretation, this means that patients diagnosed with a completely normal mucosa showed a 
milder disease compared to subjects with intraepithelial lymphocytosis at microscopic evaluation 
and placed on GFD. Also, it suggests that the latter may be the subgroup of PCD patients which 
most benefit from early treatment in the long term. 
In our study we also examined the effects of a GCD in asymptomatic PCD patients. Over a six-year 
follow-up period, 69% of patients on GCD developed CD-related symptoms, 46% developed 
villous atrophy and 61% IMD, without statistically significant differences between the two 
histological groups. As mentioned earlier, one of the most important questions with regard to adult 
PCD concerns the actual need for commencing GFD in PCD patients and the long-term risks of 
continuing GCD instead, especially in terms of the possible development of villous atrophy, IMD 
and neoplastic complications [11–15, 17]. 
In a pediatric population of 175 asymptomatic cases, Auricchio et al [11] found that the progression 
from PCD to overt CD in children was observed in 14%, 27%, and 33%, over a 3-year, 6-year, and 
9-year follow-up period, respectively. A study by Lionetti, with a shorter follow-up, has reported 
progression from PCD to overt CD in 5% of the children studied [19]. Data for the adult population 
are limited. In a 3-year study including 16 asymptomatic patients on GCD, Volta et al [17] reported 
that only one of them (6%) developed mucosal flattening. The Authors concluded that GFD was not 
recommended in asymptomatic adults with PCD, since they did not tend to develop villous atrophy. 
Very recently, in a 12-month study conducted with 57 adult Indian PCD patients, Kondala et al [20] 
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observed the development of overt CD (Marsh 3) in only four patients (7%). The Authors did not 
justify starting GFD in all patients with PCD in India.  
By contrast, in a study by Biagi et al [14] on 24 PCD cases followed-up for 20 months, 
approximately 21% of the subjects progressed from PCD to villous atrophy. These authors proposed 
that the cumulative probability of mucosal flattening was high, but the time of flattening was totally 
unpredictable. Moreover, in a randomized controlled clinical study, Kurppa et al [12] found that the 
small-bowel mucosal villous architecture deteriorated - and the symptoms and abnormal antibody 
titers persisted - in all patients in the GCD arm (Marsh 1–2), while in the GFD arm (Marsh 1–2) 
symptoms improved, antibody titers decreased, and mucosal inflammation diminished in the same 
way of CD patients with atrophy. The Authors concluded that all subjects with non-atrophic 
enteropathy benefited from GFD. Zanini et al [13] demonstrated that mild enteropathy did not mean 
mild disease, suggesting that CD patients with Marsh 1-2 deserved treatment with GFD on clinical 
grounds, independently of any consideration around the natural history of the disease. In accordance 
with findings from these Authors, our study documented an evolution from PCD to overt CD in 
46% of cases during a six-year follow-up period. We therefore suggest that adult PCD patients 
deserve early treatment with GFD. We also suggest that, given the high prevalence of family history 
for this condition [13,21], the lower prevalence of villous atrophy found in some studies could be 
related to a reduced gluten intake in a family setting where another member is already on GFD. 
In our study, patients who continued on GCD had a statistically significant higher risk of 
developing CD-related IMD than patients who were placed on GFD (61% vs 18%, p=0.03, 
OR=3.3). Although the GFD does not prevent the occurrence of IMD [22], in this population the 
early onset of treatment could reduce the incidence, or at least delay the occurrence, of autoimmune 
diseases. In our opinion, our findings, along with those in the literature mentioned above, suggest 
that all PCD patients should start an early dietetic treatment, regardless of the presence or absence 
of symptoms. 
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In our study, we found no antibodies disappearance or fluctuation in patients on a GCD. This result 
was in contrast with previous studies [10,11,14,17], which found a high prevalence (up to 31.5%) of 
antibody markers disappearance or fluctuation in asymptomatic PCD patients on GCD. Probably, 
this observation is due to small size of our population. 
Our study presents some limitations, which we briefly discuss. Firstly, our sample size is relatively 
small, although not dissimilar from that found in other studies [14,17]. This is partly due to the high 
percentage (76.7%) of symptomatic patients found in our study population and, more generally, in 
the adult PCD population [14,17]. Moreover, our study is based upon current clinical management 
practice that has been retrospectively analyzed. Further prospective and multicentric studies 
including larger population samples are needed to confirm our data and to inform official guidance 
on the question of dietary treatment. Secondly, we did not evaluate anti-tTG2 IgA intestinal 
deposits. Several previous studies have underlined the importance of tissue deposits in supporting 
CD diagnosis, especially in EMA-negative patients [10,11,17,23,24]. However, this investigation 
would have not added essential value to our study as, in order to avoid selection biases, we enrolled 
only PCD patients with EMA positivity, although all subjects in Group A expressed a slight 
positivity, as it is to be expected in the absence of mucosal damage [13,23,25]. Moreover, we were 
unable to evaluate the eventual reduction of gluten intake in our patients. 
In summary, the present study demonstrated that all symptomatic adult PCD patients clinically 
improved after gluten withdrawal. After commencing GFD, patients with positive CD serology but 
normal mucosa (Marsh 0) showed a milder disease compared to patients with Marsh 1 histology; 
probably, these patients can be considered the subgroup of PCD patients which most benefits from 
early GFD. Remarkably, also asymptomatic PCD patients should start GFD, because they are at risk 
of developing villous atrophy and autoimmune diseases in the long term.  
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FIGURE LEGENDS 
 
Figure 1. Development of gluten-related symptoms (diarrhoea, abdominal pain, weight loss, 
anemia, recurrent miscarriages, hepatic steatosis, dental enamel hypoplasia, hypertransaminasemia), 
villous atrophy and immune-mediated diseases (Hashimoto’s thyroiditis and psoriasis) during a 6-
year follow-up in patients in Group A (individuals with normal histology - Marsh 0) and Group B 
(subjects with Marsh 1 type histology) kept on gluten containing diet (GCD).  
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Table 1. Baseline demographic and serological features of potential CD patients at time of 
diagnosis. Group A (individuals with normal histology - Marsh 0); Group B (subjects with 
Marsh 1 type histology). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Group A Group B p 
Number of patients 21 35 0.1 
Males 
n (%) 
4 (19) 11 (31) 0.4 
Age (years) 
(mean + SD) 
31.3 + 15.7 32 + 19.5 0.9 
CD family history 
n (%) 
10 (47) 18 (51) 0.8 
Pre-existent IMD 
n (%) 
2 (10) 4 (11) 0.8 
Symptoms 
n (%) 
15 (71) 28 (80) 0.8 
Weight (Kg) 
(mean + SD) 
66.8 + 16.3 60 + 10 0.06 
Anti-tTG (U/mL) 
(mean + SD) 
18.9 + 9.3 19.7 + 13.4 0.8 
EMA positivity 
n (%) 
21 (100)* 35 (100) 1 
HLA DQ2 
n (%) 
20 (95) 33 (94) 0.8 
Hemoglobin (g/dL) 
(mean + SD) 
12.7 + 1.1 13.2 + 1.6 0.3 
Ferritin (ng/mL) 
(mean + SD) 
64.6 + 110.3 58.5 + 58.7 0.7 
Cholesterol (mg/dL) 
(mean + SD) 
172.9 + 34.2 170.3 + 38.6 0.8 
Triglycerides 
(mg/dL) 
(mean + SD) 
101 + 57 98.6 + 49.4 0.8 
Serum albumin 
(g/dL) 
(mean + SD) 
4.5 + 0.3 4.3 + 0.5 0.1 
 20 
*Although slight positivity in all subjects 
n=number; SD=standard deviation; CD=coeliac disease; IMD=immuno-mediated diseases; anti-tTG=anti-tissue 
transglutaminase antibodies; EMA=anti-endomysial antibodies 
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Table 2. Clinical and serological features of potential CD patients after six years of gluten free 
diet regimen. Group A (individuals with normal histology - Marsh 0); Group B (subjects with 
Marsh 1 type histology). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n=number; SD=standard deviation; CD=coeliac disease;  IMD=immuno-mediated diseases; anti-tTG=anti-tissue 
transglutaminase antibodies; EMA=anti-endomysial antibodies 
 
 
 Group A Group B p 
Number of patients 15 28 0.1 
New IMD 
n (%) 
0 (0) 8 (28) 0.03 
Response to GFD 
n (%) 
15 (100) 28 (100) 1 
Weight (Kg) 
(mean + SD) 
69.1 + 12.4 68.4 + 15.6 0.8 
Anti-tTG (U/mL) 
(mean + SD) 
1.3 + 0.9 1.2 + 0.9 0.9 
EMA positivity 
n (%) 
0 (0) 0 (0) 1 
Hemoglobin (g/dL) 
(mean + SD) 
13.2 + 1.3 13.7 + 1.7 0.3 
Ferritin (ng/mL) 
(mean + SD) 
76.6 + 98.7 74.5 + 68.9 0.9 
Cholesterol (mg/dL) 
(mean + SD) 
184.9 + 38.4 192.3 + 41.8 0.5 
Triglycerides (mg/dL) 
(mean + SD) 
138.4 + 64.2 135.3 + 76.8 0.8 
Serum albumin (g/dL) 
(mean + SD) 
4.6 + 0.2 4.5 + 0.3 0.3 
